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Abstract
Ischemic preconditioning (IPC) is a well-known phenomenon in which tissues are exposed
to a brief period of ischemia prior to a longer ischemic event. This technique produces tissue
tolerance to ischemia reperfusion injury (IRI). Currently, IPC’s mechanism of action is poorly
understood. Using a porcine single kidney model, we performed remote IPC with renal IRI
and evaluated the IPC mechanism of action. Following left nephrectomy, 15 female York-
shire pigs were divided into three groups: no IPC and 90 minutes of warm ischemia (con-
trol), remote IPC immediately followed by 90 minutes of warm ischemia (rIPCe), and remote
IPC with 90 minutes of warm ischemia performed 24 hours later (rIPCl). Differential gene
expression analysis was performed using a porcine-specific microarray. The microarray
analysis of porcine renal tissues identified 1,053 differentially expressed probes in precondi-
tioned pigs. Among these, 179 genes had altered expression in both the rIPCe and rIPCl
groups. The genes were largely related to oxidation reduction, apoptosis, and inflammatory
response. In the rIPCl group, an additional 848 genes had altered expression levels. These
genes were primarily related to immune response and inflammation, including those coding
for cytokines and cytokine receptors and those that play roles in the complement system
and coagulation cascade. In the complement system, the membrane attack complex was
determined to be sublytic, because it colocalized with phosphorylated extracellular signal-
regulated kinase. Furthermore, alpha 2 macroglobulin, tissue plasminogen activator, uter-
ine plasmin trypsin inhibitor, and arginase-1 mRNA levels were elevated in the rIPCl group.
These findings indicate that remote IPC produces renoprotective effects through multiple
mechanisms, and these effects develop over a long timeframe rather than immediately fol-
lowing IPC.
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Introduction
Ischemic preconditioning (IPC) is an effective method for protecting organs prior to ischemia
reperfusion injury (IRI). Since the initial report of the IPC phenomenon, numerous studies
have tried to incorporate IPC to protect various organs, including the heart, lung, small intes-
tine, liver, brain, and kidney [1–6]. There are 2 types of IPC. Local IPC involves brief interrup-
tion of blood supply to the target organ alternated with brief episodes of reperfusion applied
prior to prolonged lethal ischemia. In remote IPC, intermittent brief ischemia and reperfusion
is applied to an organ (e.g., a limb or the intestine) distant to the target organ. For organs that
are vulnerable to short-term ischemic injury, such as the brain, heart, or kidney, remote IPC is
the preferred method [7–9].
Many studies have demonstrated renoprotective effects for remote IPC in renal IRI using
rodent animal models [10]. Remote IPC can decrease blood urea nitrogen, creatinine, and mal-
ondialdehyde levels [11, 12]. In addition to these biomarkers, histological evidence supporting
the renoprotective effects of remote IPC has been reported [13]. While encouraging, these
results do not directly translate to the clinical application of remote IPC in humans, because
human renal physiology is different from that of rodents [14]. While a few studies have investi-
gated remote IPC in large animals [10, 15, 16], most large animal studies focused on local IPC
[17–22]. To safely use IPC in human renal IRI, we first need to determine the most effective
IPC protocol and understand its exact mechanism of action. Previous studies have not defined
a mechanism of action for remote IPC. Several potential mechanisms have been suggested,
including production of adenosine, bradykinins, opioids, antioxidants, humoral substances,
and inflammatory molecules; however, there are no accurate and comprehensive reports
regarding the remote IPC mechanism of action [23–27]. Recently, gene microarray technology
has been used to analyze the molecular basis of many diseases. For example, genetic changes
produced by renal IRI have been analyzed using microarrays [28]. However, microarray analy-
sis of remote IPC tissues is limited, and, to our knowledge, there has been no analysis of the
transcriptome of renal tissue after remote IPC [29, 30].
In our previous study, we concluded that remote IPC elicited fewer renal injury biomarkers
following IRI; however, more animal studies deciphering the detailed remote IPC mechanism
are needed before IPC can be incorporated into human surgeries [31]. In this study, we used a
microarray analysis to evaluate the effect of the time between IPC and IRI in remote IPC and
identify the exact mechanism of action for remote IPC in renal IRI using a porcine single kid-
ney model.
Materials and Methods
Animals and design of experiments
The study was approved by the Institutional Animal Care and Use Committee, Yonsei Univer-
sity Health System in accordance with the ‘Guide for the Care and Use of Laboratory Animals’
published by the National Institutes of Health and was conducted according to the principles
of the Declaration of Helsinki. A total of 15 female Yorkshire pigs (20 weeks old; 35–38 kg, S. s.
domesticus) were used (XP Bio Inc., Anseong-si, Korea). The animals were individually caged
for 10 days before the start of the experiment and received standard laboratory food with free
access to water. In a prospective design, pigs were allocated randomly to three experimental
groups (Fig 1). Group 1 pigs (control, n = 5) underwent right renal ischemia without IPC.
Group 2 pigs (rIPCe, n = 5) underwent remote IPC just before right renal ischemia, i.e., an
early time window. Group 3 pigs (rIPCl, n = 5) underwent remote IPC with right renal ische-
mia 24 hours later, i.e., a late time window. All three groups underwent the same protocol for
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preoperative care, anesthesia, postoperative care, and sacrifice. Prior to anesthesia administra-
tion, the pigs were starved for 8 hours. Anesthesia was induced by intramuscular tiletamine-
zolazepam (5 mg/kg) and xylazine (2 mg/kg). Following endotracheal intubation, anesthesia
was maintained using controlled ventilation with 2% isoflurane at a respiratory rate of 15/min.
All procedures were performed laparoscopically with standard 5-mm 3-port access by two
Fig 1. Experimental protocol. Blue cylinders represent the time zone of clamping and clear cylinders
represent the declamping. Control, no IPC and 90 minutes of warm ischemia; rIPCe, 40 minutes of remote
IPC immediately followed by 90 minutes of warm ischemia; and rIPCl, 40 minutes of remote IPC with 90
minutes of warm ischemia 24 hours later.
doi:10.1371/journal.pone.0141099.g001
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surgeons (W.K.H. and Y.E.Y.). During the procedure, intraperitoneal pressure was maintained
at 12 mmHg. To create the single kidney porcine model, we first performed a left nephrectomy.
After a 1-week renal compensation period, we performed the IPCs and right renal ischemias,
as appropriate, based upon the group assignment. We performed two cycles of IPC by clamp-
ing the right external iliac artery for 10 minutes followed by 10 minutes of reperfusion. We per-
formed warm ischemia for the right kidney by clamping the right renal artery and vein
together for 90 minutes. Antibiotic prophylaxis was administered using amoxicillin clavulanate
(15 mg/kg/day), and meloxicam (0.2 mg/kg/day) was used as postoperative analgesia. Pigs
were individually housed and had free access to water and feed. Every pig was sacrificed 72
hours postoperatively. Pigs were administered an intramuscular injection of ketamine (25 mg/
kg) and xylazine (2 mg/kg) followed by an intravenous potassium chloride injection. Renal tis-
sues were harvested immediately and stored in a -80°C freezer until the microarray analysis
was performed.
Microarray analysis
Total RNA was extracted from tissues using TRIzol (Invitrogen Life Technologies, Carlsbad,
CA, USA) according to the manufacturer's protocol and purified with the RNeasy Mini Kit
(Qiagen Inc., Valencia, CA, USA). RNA labeling and hybridization were performed using the
Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technolo-
gies, v6.5, Palo Alto, CA, USA). Briefly, 200 ng of total RNA from each sample was linearly
amplified and labeled with Cy3-dCTP. The labeled cRNAs were hybridized onto the Porcine
Gene Expression Microarray, 4×44K (Agilent Technologies). The hybridized array was imme-
diately scanned with an Agilent Microarray Scanner (Agilent Technologies). Raw data were
extracted using the Agilent Feature Extraction Software (Agilent Technologies, v11.0.1.1). The
selected gProcessedSignal value was transformed logarithmically and normalized using the
quantile method. The expression data were quantified as fold change, and the statistical signifi-
cance was determined using an independent t-test. We adjusted the p-value to account for the
false discovery rate using the Benjamini-Hochberg algorithm. A K-means clustering analysis
was performed using the MacQueen algorithm to compare the expression profiles. Hierarchical
cluster analysis was performed using complete linkage and Euclidean distance as a measure of
similarity. Gene-enrichment and functional annotation analysis for significant probes was per-
formed using DAVID (Database for Annotation, Visualization and Integrated Discovery v6.7,
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; http://david.abcc.
ncifcrf.gov). All data analysis and differentially expressed gene visualization was performed
using the R statistic software (R version 3.0.1, R Foundation for Statistical Computing, Vienna,
Austria; http://www.r-project.org).
Immunohistological staining and microscopic analysis
Kidneys were embedded in paraffin, and 2-μm sections were prepared for fluorescent immu-
nostaining and immunohistochemical staining. Deparaffinized renal sections were fixed and
incubated in PBS with 5% bovine serum albumin and 0.05% Tween 20 (PBST) at room temper-
ature for 1 h in a humidified chamber to block non-specific binding sites. The sections were
incubated overnight with the primary antibodies in PBST buffer with 3% BSA at 4°C. The pri-
mary antibodies used were anti-C3c-FITC (Abcam, Cambridge, MA, USA), mouse anti-mem-
brane attack complex (MAC; Abcam), and rabbit anti-phosphorylated extracellular signal-
regulated kinase (ERK) 1 and ERK2 (P-ERK; Cell Signaling Technology Inc., Danvers, MA,
USA). After washing, the sections were incubated with fluorophore-conjugated secondary anti-
bodies (anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 594, Invitrogen Life
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Technologies) for 1 h at room temperature. The sections were mounted using Vectashield
mounting medium with 4ʹ,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA,
USA). For immunohistochemical staining, the slides were pretreated in 0.01 M citric acid
buffer (pH 6.0) for 10 minutes. After blocking, sections were incubated with primary antibody
against P-ERK at 4°C overnight. After washing, sections were exposed to a streptavidin-horse-
radish-peroxidase complex for 30 minutes at 37°C and visualized with 3,3ʹ-diaminobenzidine.
Terminal Deoxynucleotidyl Transferase-mediated dUTP-X Nick End
Labeling (TUNEL) staining
To detect apoptotic cells, TUNEL staining was performed using a TACS1 2 TdT-DAB In Situ
Apoptosis Detection Kit (Trevigen, Inc., Gaithersburg, MD, USA) according to the manufac-
turer’s instructions. Kidneys were embedded in paraffin, and 2-μm sections were prepared for
TUNEL staining. After deparaffinization, digestion with proteinase K (15 minutes), and
quenching of endogenous peroxidase in 2% H2O2 (5 minutes), formalin-fixed renal sections
were immersed in the TdT buffer and incubated with TdT, 1 mMMn2+, and biotinylated
dNTP at 37°C for 60 minutes. Then the sections were incubated with streptavidin–horseradish
peroxidase at room temperature for 10 minutes and immersed in diaminobenzidine substrate
for 5 minutes. The slides were then counterstained with 1% methyl green for 30 seconds.
Reverse transcriptase-polymerase chain reaction
Microarray results were validated using RT-PCR. Briefly, cDNA was synthesized from purified
RNA using oligo dT-primers with SuperScriptTM II reverse transcriptase (Invitrogen Life Tech-
nologies) according to the supplier’s protocol. Primer sequences used in the study are listed in
S1 Table. Equal volumes of amplified cDNAs were loaded into 1.5% agarose gels and separated
by electrophoresis. The bands were identified using a Bio-Rad Gel Doc 2000 system with Bio-
Rad TDS Quantity One Software.
Results
Microarray
All RNA samples had 260/280 ratios between 1.8–2.2, and agarose gel electrophoresis showed
two clear bands for 28S and 18S rRNA. In the microarray, 43,603 probes were detected.
Among those, 1,053 probes had significant intensity changes. The criteria for significance was |
fold change|2 and a p-value<0.05.
The K-mean hierarchal cluster analysis divided all 1,053 genes into two clusters (Fig 2).
Cluster 1 consisted of 400 genes that were downregulated in rIPCe relative to the control group
and downregulated further in rIPCl. Cluster 2 consisted of 653 genes that were upregulated in
rIPCe relative to the control group and upregulated further in rIPCl.
The rIPCe group had 198 genes with expression level changes; 96 genes were upregulated,
and 102 genes were downregulated compared to those in the control group (Fig 3). The rIPCl
group had 1,027 genes with expression level changes; 640 genes were upregulated, and 387
genes were downregulated. Fig 3 shows that nearly all genes with altered expression in the
rIPCe group were also differentially expressed in the rIPCl group.
Altered gene expression shared by rIPCe and rIPCl
The rIPCe and rIPCl groups had 179 genes with similar expression levels; 85 genes were upre-
gulated and 94 genes were downregulated compared to the control group genes. The similarly
expressed genes were primarily related to oxidation, inflammation, macromolecule complex
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assembly, and apoptosis (S2 Table). Gene ontology enrichment analysis confirmed that some
of the genes were related to oxidative reduction, inflammatory response, macromolecular com-
plex assembly, and apoptosis. Gene ontology analysis also identified additional functions (Fig
4); however, these genes were not part of a specific pathway.
Altered gene expression in the rIPCl group
Among the 1,053 genes in the rIPCl group with altered expression levels compared to the con-
trol group, 848 genes were altered in the rIPCl group only. Of those, 555 genes were upregu-
lated, and 293 genes were downregulated. Gene ontology enrichment analysis showed that the
rIPCl group genes with altered expression levels were related to immune response, response to
wounding, proteolysis, and inflammation rather than apoptosis or oxidation (Fig 5).
Functional classification of genes
We attempted to identify some potential IPC mechanisms with DAVID. When we examined
the entire list of altered expression level genes, DAVID noted several enriched pathways (S3
Fig 2. Hierarchal cluster analysis of 1,053 altered genes. The genes were divided into two clusters via K-
mean hierarchal cluster analysis. Cluster 1 genes are downregulated (green) in the rIPCe and rIPCl. Cluster 2
genes are upregulated in rIPCl. rIPCe, remote ischemic preconditioning immediately prior to ischemia (early);
rIPCl, remote ischemic preconditioning followed by ischemia 24 hours later (late).
doi:10.1371/journal.pone.0141099.g002
Fig 3. Venn diagrams of altered gene expression. rIPCe, remote ischemic preconditioning immediately
prior to ischemia (early); rIPCl, remote ischemic preconditioning followed by ischemia 24 hours later (late).
doi:10.1371/journal.pone.0141099.g003
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Table), including the complement system, the coagulation cascade, and cytokines and cytokine
receptors (Fig 6). The heatmap shows that most of these genes were upregulated in the rIPCl
group (Fig 6).
Fig 4. Major enriched gene ontology biological processes for the 179 genes with similar expression
levels in the rIPCe and rIPCl groups. Similar gene ontology terms were excluded to avoid repetition. rIPCe,
remote ischemic preconditioning immediately prior to ischemia (early); rIPCl, remote ischemic
preconditioning 24 hours followed by ischemia 24 hours later (late).
doi:10.1371/journal.pone.0141099.g004
Fig 5. Major enriched gene ontology biological processes for the 848 genes with altered expression
levels in the rIPCl group only. Similar gene ontology terms were excluded to avoid repetition. rIPCl, remote
ischemic preconditioning followed by ischemia 24 hours later (late).
doi:10.1371/journal.pone.0141099.g005
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The complement system
We detected expression changes in many complement cascade genes in the rIPCl group com-
pared to the control group (Fig 7). The classical pathway genes C1q, C1s, and C2 were upregu-
lated. The alternative pathway genes C3 and factor B were also upregulated. However,
Fig 6. Heatmap signature of suggested pathways by DAVID. rIPCe, remote ischemic preconditioning
immediately prior to ischemia (early); rIPCl, remote ischemic preconditioning followed by ischemia 24 hours
later (late).
doi:10.1371/journal.pone.0141099.g006
Fig 7. Genes in the complement systemwith altered expression levels. The yellow boxes indicate
upregulated gene expression (fold change2 and p < 0.05). The red lines indicate inhibition.
doi:10.1371/journal.pone.0141099.g007
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complement inhibitors, including serpin peptidase inhibitor, clade G (C1 inhibitor), member 1
(SERPING1), C4b-binding protein (C4BP), and factor H, were also upregulated.
To confirm complement pathway activation, we performed immunofluorescent staining for
C3c, a cleavage product of activated C3 and MAC, using a monoclonal antibody against neoanti-
gen (Fig 8A). C3c and MAC deposition was observed in both the rIPCe and rIPCl groups. The
relative fluorescence intensity of C3c andMAC was higher in the rIPCl group than that in the
rIPCe group (Fig 8B). Because ERK is activated by sublytic MAC formation, we evaluated P-ERK
levels in the renal tissues. The rIPCl group renal tubular cells were strongly positive for P-ERK
staining, whereas control group renal tubular cells showed no staining (Fig 8C). MAC and
P-ERK colocalization was also detected in the rIPCl group (Fig 8D), and the Pearson's coefficient
for MAC and P-ERK colocalization in 12 fields was higher in the rIPCl group than in the control
and rIPCe groups (Fig 8E). TUNEL staining revealed that the rIPCl group had fewer apoptotic
cells in renal tubules compared with those in the control or rIPCe groups (Fig 8F).
The coagulation cascade
Many of the differentially expressed genes in the rIPCl group were involved in the coagulation
cascade (Fig 9). Plasma thromboplastin antecedent (IX), protein C, and carboxypeptidase B2
Fig 8. Immunohistochemical analysis of pig renal tissue. (A) C3c (green) and MAC (red) deposition was observed in confocal images of renal tissues,
scale bar = 100 μm; DAPI, 4ʹ,6-diamidino-2-phenylindole (blue). (B) Relative fluorescence intensity of C3c and MAC staining was increased in rIPCe and
rIPCl, *p < 0.05 vs. Control. (C) P-ERK IHC shows that ERK is activated in rIPCe and rIPCl, scale bar = 100 μm. (D) MAC (red) and P-ERK (green)
colocalization was observed in confocal images of renal tissues, scale bar = 100 μm. (E) Pearson's coefficient for MAC and P-ERK colocalization (in 12
fields) was higher in rIPCe and rIPCl, *p < 0.05 vs. Control. (F) TUNEL staining showed fewer apoptotic renal tubular cells in the rIPCl group compared with
Control, scale bar = 50 μm. MAC, membrane attack complex; P-ERK, phosphorylated extracellular signal-regulated kinase; rIPCe, remote ischemic
preconditioning immediately prior to ischemia (early); rIPCl, remote ischemic preconditioning followed by ischemia 24 hours later (late); TUNEL, terminal
deoxynucleotidyl transferase dUTP nick end labeling.
doi:10.1371/journal.pone.0141099.g008
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(CPB2) were downregulated in the rIPCl group. In contrast, alpha 2 macroglobulin (A2M), tis-
sue plasminogen activator (PLAT), and urokinase-type plasminogen activator (PLAU) were
upregulated in the rIPCl group.
We used RT-PCR analysis to validate the gene expression changes detected during the
microarray analysis. The mRNA levels of A2M, PLAT, and uterine plasmin trypsin inhibitor
(UPTI) were elevated in both the rIPCe and rIPCl groups when compared with those in the
control group (S1 Fig). While the A2MmRNA level in the rIPCl group was not upregulated to
the same degree as that in the rIPCe group, the A2M expression levels in both groups were
markedly elevated compared to that of the control group. These results were consistent with
the microarray data. However, the RT-PCR analysis did not demonstrate any changes in the
PLAU expression level in either the rIPCe or rIPCl groups, which contradicted the microarray
data indicating that PLAU expression was upregulated in the rIPCl group (S1 Fig).
Cytokines and cytokine receptors
S4 Table lists the cytokines and cytokine receptors that the microarray analysis identified as
differentially expressed in the rIPCe and rIPCl groups. Most of the cytokines and cytokine
receptors were upregulated in the rIPCl group compared to those in the control group. We per-
formed RT-PCR to validate the expression levels of interleukin 10 (IL-10) and transforming
growth factor beta 1 (TGF-β1). The IL-10 and TGF-β1mRNA levels were upregulated in both
the rIPCe and rIPCl groups compared to those in the control group, confirming the microarray
results (S1 Fig and S4 Table). The RT-PCR also verified that the M2 mononuclear phagocyte
marker, arginase-1 (ARG-1) mRNA expression level was upregulated in both the rIPCe and
rIPCl groups (S1 Fig).
Discussion
Renal IRI, which is caused by cardiopulmonary bypass, partial nephrectomy, and renal trans-
plantation, is an emerging clinical problem, because acute renal injury can result in end-stage
renal disease [32]. Chronic kidney disease increases the risk of death and cardiovascular mor-
bidity, even when dialysis is unnecessary [33]. With this in mind, IPC may be an alternative
strategy to preserve renal function after IRI.
In our previous study, we demonstrated that remote IPC with the late window group had
lower urinary kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin
(NGAL) levels than the control group following IRI [31]. Gardner et al. also demonstrated that
Fig 9. Genes in the coagulation cascade with altered expression levels. Yellow boxes indicate
upregulated genes (fold change2 and p < 0.05). Green boxes indicate downregulated genes (fold change
-2 and p < 0.05). Red lines indicate inhibition.
doi:10.1371/journal.pone.0141099.g009
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remote IPC has a renoprotective effect in renal IRI in a porcine model [16]. Our results demon-
strate that numerous gene expression levels were altered in the rIPC groups, especially in the
rIPCl group. Hanto et al. verified that intraoperative administration of inhaled carbon monox-
ide reduces delayed graft function in a porcine delayed kidney transplantation model [34]. In
that study, the authors hypothesized that the expression of antioxidant, proinflammatory, and
reparative gene families improved renal function. Jun et al. performed a microarray study dem-
onstrating a protective effect for IPC in a lung IRI model [29]. In their study, the differentially
expressed genes had roles in inflammation, apoptosis, oxidation, antioxidation, and metabo-
lism. While their study evaluated lung tissue rather than renal tissue, the microarray analysis
results are similar to those from our present study, which provides additional evidence for our
hypothesis that IPC affects numerous pathways rather than one specific pathway. Our microar-
ray data suggest that IPC induces changes in the complement system, the coagulation cascade,
and various cytokines and cytokine receptors.
The complement system
Of the three major complement pathways, the alternative and classical pathways are active in
the kidney [35, 36]. A previous study confirmed that the complement system, especially the C3
protein, plays a major role in tissue damage in IRI [37]. In our study, the classical pathway pro-
teins C1s, C1q, and C2 and the alternative pathway protein C3 were upregulated in the rIPCl
group. However, inhibitors of these proteins (SERPING1, C4BP, and factor H) were also upre-
gulated. In a kidney transplantation model, Castellano et al. demonstrated that C1 inhibitor
infusion significantly reduced tubular damage and tubular epithelial cell apoptosis [38]. These
authors concluded that classical and lectin pathway inhibition may provide an alternative ther-
apeutic approach for renal IRI. Other studies demonstrated that a mutation in the factor H
gene, a regulator of the alternative pathway, is a risk factor for some renal diseases, which sup-
ports the idea that complement inhibition has beneficial effect in IRI [39]. Factor H also has a
major role in renal IRI, and a recombinant form of factor H reduces complement activation in
the tubulointerstitium after renal IRI [40].
Our microarray data demonstrated upregulation of various complement cascade proteins
and IRI-protective regulatory proteins, such as SERPING1 and Factor H. These results suggest
that IPC may reduce IRI damage by neutralizing the complement cascade. We did detect
increased C3c and MAC staining in rIPCe and rIPCl tissues; however, phosphorylated ERK
colocalized with MAC. The colocalization data suggest that sublytic concentrations of MAC
were present in the tissue [41]. Sublytic MAC concentrations reduce the infarction size in
hearts [42]. Furthermore, sublytic MAC concentrations induce proliferation in specific cells,
such as human aortic smooth muscle cells [43]. Sublytic doses of MAC desensitize cells and
make them resistant to cell lysis through ERK activation [44]. Our TUNEL results demon-
strated that there were fewer apoptotic cells in the rIPCl group than in the control and rIPCe
groups, which agrees with previous studies.
The coagulation cascade
In our study, we stopped blood flow to produce renal IRI. As a result, coagulation cascade-
related genes, such as PLAT, CPB2, and A2M, were differentially expressed in the rIPCl group.
These data suggest that IPC may reduce ischemic injury by lysing blood clots. However, these
genes may also regulate non-coagulation cascade pathways. Roelofs et al. showed that PLAT
expression reduces neutrophil influx and preserves renal function during renal IRI using PLAT
knockout mice [45]. Therefore, PLATmay also play an anti-inflammatory role in IPC. CPB2
mRNA expression was downregulated in the rIPCl group compared with the control group in
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our study. CPB2 is a thrombin-activated fibrinolysis inhibitor that eliminates fibrin carboxyl-
terminal residues [46]. CPB2 downregulation may be beneficial during IRI, because reduced
CPB2 expression increases fibrinolysis. The microarray analysis also showed that A2M expres-
sion increased in both the rIPCe and rIPCl groups (2.00- and 2.86-fold changes, respectively),
which was verified by RT-PCR. A2M inhibits coagulation by inactivating thrombin and inhib-
its clot lysis by inactivating plasmin [47]. A2M also inhibits proteolysis by reducing protease
activity [48]. Therefore, A2Mmay reduce ischemic injury following remote IPC by inhibiting
coagulation and proteolysis.
Cytokines and cytokine receptors
CXCL10 and CXCL11 were upregulated in the rIPCe and rIPCl groups in our study. IFN-γ,
which is a major macrophage activator, may upregulate the expression of chemokines, such as
CXCL9, CXCL10, and CXCL11, in renal proximal tubular epithelial cells [49]. Fibronectin and
fibrinogen can then bind to CXCL10 and CXCL11, and the interaction between fibronectin
and CXCL11 potentiates wound repair [50]. The anti-inflammatory IL-10 was also upregulated
in the rIPCl group. Administering exogenous IL-10 to normal rats stimulates mesangial cell
growth, both in vitro and in vivo [51]. Mesangial cells are critical for maintaining renal func-
tion, because they provide structural support to the glomerulus and affect the glomerular filtra-
tion rate [52]. In addition, increased IL-10 levels decreased proteinuria and reduced interstitial
fibrosis and glomerulosclerosis in a 5/6 nephrectomized rat model [53]. IL-10 also regulates
the synthesis of cystatin C, which controls mesangial cell proliferation [54, 55]. Therefore, IL-
10 may reduce ischemic injury by promoting mesangial cell proliferation and viability after
remote IPC.
TGF-β, another anti-inflammatory cytokine, was upregulated in both rIPC groups com-
pared with the control group. In the kidney, only mesangial cells secrete and activate TGF-β
[56]. TGF-β can cause renal epithelial cell hypertrophy [57]. Mesangial cells initiate compensa-
tory renal hypertrophy, even though tubular cells are the major players in the hypertrophic
process [58]. Sinuani et al. verified that mesangial cells control the degree of compensatory
tubular cell hypertrophy by regulating TGF-β-induced IL-10 expression levels [58]. IL-10 syn-
thesis inhibition in mesangial cells results in a significant TGF-β expression reduction in rem-
nant kidneys. Consequently, there is a 25% reduction in compensatory tubular cell
hypertrophy. Taken together, these findings suggest that IPC may contribute to anti-inflamma-
tory effects and tubular cell reproduction by altering IL-10 and TGF-β gene expression. To our
knowledge, there are no reports on the roles of IL-10 or TGF-β in relation to the molecular
mechanism of remote IPC. Further work is needed to verify the roles of IL-10 and TGF-β in
remote IPC and to determine their roles in the kidney.
Conclusions
These results suggest that remote IPC produces renoprotective effects in renal IRI through
multiple mechanisms rather than one specific pathway. Remote IPC produces expression
changes in genes related to inflammatory cytokines and cytokine receptors, apoptosis, oxida-
tion and antioxidation, ion channels and aquaporins, metabolism, and the cytoskeleton. Our
data suggest that the complement system, the coagulation cascade, and various cytokines and
cytokine receptors are the major mechanisms of remote IPC. The changes in these pathways
were more pronounced when renal IRI was performed 24 hours after remote IPC rather than
immediately afterwards. This study did not determine the optimal time frame to perform
remote IPC prior to renal IRI; however, our results provide further evidence that remote IPC is
renoprotective for renal IRI. Future studies will focus on elucidating the optimal time window
Renoprotective Mechanism of Remote Ischemic Preconditioning
PLOS ONE | DOI:10.1371/journal.pone.0141099 October 21, 2015 12 / 16
for remote IPC and further defining the functional roles of the various genes identified in this
study.
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